Amylyx Reports $317M Cash, Eyes Q3 Phase 3 Data for Avexitide PBH Trial
Amylyx closed Q4 with $317 million cash, extending runway into 2028, and set 2026 goals to deliver Phase 3 LUCIDITY top-line data in Q3, advance NDA readiness and strengthen 2027 launch preparations for avexitide 90 mg daily in post-bariatric hypoglycemia. Prior Phase 2 results showed a 64% reduction in level 2/3 events (p = 0.0031).
1. Q4 Financial Position
Amylyx closed Q4 with $317 million in cash, extending its cash runway into 2028. Management highlighted pipeline priorities including late-stage avexitide development and early-stage programs AMX0318 and AMX0114, supporting continued operations through key clinical milestones.
2. Phase 3 LUCIDITY Trial Plan
The Phase 3 LUCIDITY trial is evaluating once-daily 90 mg avexitide in post-bariatric hypoglycemia patients, using a primary endpoint of reduced level 2/3 hypoglycemic events through week 16. Enrollment is expected to complete this quarter with top-line results slated for Q3 2026 and potential commercialization in 2027 if approved.
3. Prior Phase 2 Efficacy Data
Prior Phase 2 data demonstrated a 64% least squares mean reduction in level 2/3 events versus baseline (p = 0.0031) with no placebo response, driving the conservative 35% effect size assumption for Phase 3. The design builds on five earlier trials to ensure robust powering and reproducibility.
4. Commercial and Regulatory Preparations
Preparation for commercialization includes NDA readiness, key hires in commercial and medical affairs, disease education initiatives, and patient identification strategies for an estimated 160,000 US post-bariatric hypoglycemia patients. Management expects an ICD-10 code this year to facilitate patient tracking, although coverage under the pharmacy benefit is anticipated without it.